HER3 as biomarker and therapeutic target in pancreatic cancer: New insights in pertuzumab therapy in preclinical models

Oncotarget

Volumn 5, Issue 16, 2014, Pages 7138-7148

  Thomas, Gaëlle ^a,b,c,d,e   Chardès, Thierry ^a,b,c,d   Gaborit, Nadège ^a,b,c,d   Mollevi, Caroline ^d   Leconet, Wilhem ^a,b,c,d   Robert, Bruno ^a,b,c,d   Radosevic Robin, Nina ^f   Penault Llorca, Frédérique ^f   Gongora, Céline ^a,b,c,d   Colombo, Pierre Emmanuel ^a,b,c,d   Lazrek, Yassamine ^a,b,c,d,g   Bras Goncalves, Rui ^a,b,c,d   Savina, Ariel ^h   Azria, David ^a,b,c,d   Bazin, Hervé ⁱ   Pèlegrin, André ^a,b,c,d   Larbouret, Christel ^a,b,c,d  

^a INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^b INSERM   (France)

^c UNIV MONTPELLIER   (France)

^d CENTRE VAL D AURELLE   (France)

^e Institut Roche de Recherche et Me decine Translationnelle   (France)

^f UNIVERSITÉ CLERMONT AUVERGNE   (France)

^g Millegen SA   (France)

^h RocheSAS Scientific Partnerships   (France)

ⁱ Parc Marcel Boiteux   (France)

Author keywords

HER2; HER3; Pancreatic cancer; Pertuzumab

Indexed keywords

9F7 F11 ANTIBODY; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE 1; NEU DIFFERENTIATION FACTOR; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TUMOR MARKER; UNCLASSIFIED DRUG; ERBB3 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL MEMBRANE; CELL VIABILITY; CONTROLLED STUDY; DIMERIZATION; DOWN REGULATION; FLOW CYTOMETRY; GENE AMPLIFICATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SURVIVAL TIME; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; FEMALE; HUMAN; METABOLISM; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; RANDOMIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; FEMALE; HUMANS; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; RANDOM ALLOCATION; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907075306     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2231     Document Type: Article

References (29)

1. Azria D, Ychou M, Jacot W, Thezenas S, Lemanski C, Senesse P, Prost P, Delard R, Masson B, Dubois JB. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cisplatin. Pancreas. 2002; 25(4):360-365.
2. Nelson N.J. Pancreatic cancer research matures. J Natl Cancer Inst. 2007; 99(19):1432-1434.
3. Jones S, Zhang X, Parsons DW, Lin JCH, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008; 321(5897):1801-1806.
4. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25(15):1960-1966.
5. Sarker D, Workman, P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res. 2007;96:213-268.
6. Larbouret C, Robert B, Navarro-Teulon I, The`zenas S, Ladjemi MZ, Morisseau S, Campigna E, Bibeau F, Mach JP, Pe`legrin A, Azria D. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res. 2007;13(11): 3356-3362.
7. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6(4):443-446.
8. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008;68(14):5878-5887.
9. Sendur MAN, Aksoy S, Altundag K. Pertuzumab in HER2-positive breast cancer. Curr Med Res Opin. 2012;28(10):1709-1716.
10. Amler LC, HER3 mRNA as a predictive biomarker in anticancer therapy. Expert Opin Biol Ther 2010;10:(9)1343-1355.
11. Landgraf R. ERBB3: Multifunctional enabler or primary actor in pancreatic cancer. Cancer Biol Ther. 2010; 10(6):564-566.
12. Friess H, Yamanaka Y, Kobrin MS, Do DA, Bu¨chler MW, Korc M. Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. Clin Cancer Res. 1995;1(11):1413-1420.
13. Liles JS, Arnoletti JP, Tzeng CWD, Howard JH, Kossenkov AV, Kulesza P, Heslin MJ, Frolov A. ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma. Cancer Biol Ther. 2010;10(6): 555-563.
14. Kim HH, Vijapurkar U, Hellyer NJ, Bravo D, Koland JG. Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein. Biochem J.1998;334(Pt 1): 189-195.
15. Simon PO Jr, McDunn JE, Kashiwagi H, Chang K, Goedegebuure PS, Hotchkiss RS, Hawkins WG. Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma. Int J Cancer. 1998:125(4):942-951.
16. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007;445(7126):437-441.
17. Lazrek Y, Dubreuil O, Garambois V, Gaborit N, Larbouret C, Le Clorennec C, Thomas G, Leconet W, Jarlier M, Pugnie`re M, Vie´ N, Robert B, Monnet C et al. Anti-HER3 Domain 1 and 3 Antibodies Reduce Tumor Growth by Hindering HER2/HER3 Dimerization and AKT-Induced MDM2, XIAP, and FoxO1 Phosphorylation. Neoplasia. 2013;15(3):335-347.
18. Gaborit N, Larbouret C, Vallaghe J, Peyrusson F, Bascoul-Mollevi C, Crapez E, Azria D, Charde`s T, Poul MA, Mathis G, Bazin H, Pe`legrin A. Time-resolved fluorescence resonance energy transfer [TR-FRET] to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies J Biol Chem. 2011;286(13):11337-1145.
19. Le Cam L, Linares LK, Paul C, Julien E, Lacroix M, Hatchi E, Triboulet R, Bossis G, Shmueli A, Rodriguez MS, Coux O, Sardet C. E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell. 2006;127: 775-788.
20. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127-137.
21. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans D, Maiese K, Scher HI, Sliwkowski MX. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002; 2(2): 127-137.
22. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005; 23(11): 2534-2543.
23. Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK. Clinical activity of pertuzumab [rhuMAb 2C4], a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006;24(26): 4324-4332.
24. Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sa´nchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, Manning HC, Chang J, Arteaga CL. Transcriptional and posttranslational up-regulation of HER3 [ErbB3] compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci USA . 2011;108(12):5021-5026.
25. Nagumo Y, Faratian D, Mullen P, Harrison DJ, Hasmann M, Langdon SP. Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity. Mol Cancer Res. 2009;7(9):1563-1571.
26. Amin DN, Sergina N, Lim L, Goga A, Moasser MM. HER3 signaling is regulated through a multitude of redundant mechanisms in HER2-driven tumor cells. Biochem J. 2012; 1;447(3):417-425.
27. Frolov A, Schuller K, Tzeng CWD, Cannon EE, Ku BC, Howard JH, Vickers SM, Heslin MJ, Buchsbaum DJ, Arnoletti JP. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. Cancer Biol Ther. 2007;6[4]:548-554.
28. Makhija S, Amler LC, Glenn D, Ueland FR, Gold MA, Dizon DS. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol.2010;28[7]:1215-1223.
29. Kaye SB, Poole CJ, Danska-Bidzin´ska A, Gianni L, Del Conte G, Gorbunova V, Novikova E, Strauss A, Moczko M, McNally VA, Ross G, Vergote I. A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer. Ann Oncol. 2013;24(1):145-152.